Phase II study of CC-5103 [lenalidomide] and rituximab in Waldenstrom's macroglobulinemia.

Trial Profile

Phase II study of CC-5103 [lenalidomide] and rituximab in Waldenstrom's macroglobulinemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top